Doctoral Thesis
Refine
Document Type
- Doctoral Thesis (7) (remove)
Language
- English (7) (remove)
Has Fulltext
- yes (7)
Is part of the Bibliography
- no (7)
Keywords
- Thioredoxine (2)
- B-Zelle (1)
- Biochemie (1)
- CANDLE (1)
- CRMP2 (1)
- Collapsin Response Mediator Protein 2 (1)
- Doxorubicin (1)
- Entwicklungsstörung (1)
- Gen (1)
- Glutaredoxin (1)
- Glutaredoxin 2 (1)
- Glutaredoxine (1)
- Glutathion (1)
- Glutathione (1)
- Insulin (1)
- Intelligenzminderung (1)
- Islets of Langerhans (1)
- Langerhans-Inseln (1)
- MICAL (1)
- Mas Rezeptor (1)
- Mas receptor (1)
- Mitochondrium (1)
- Molekularbiologie (1)
- Mutation (1)
- NADPH oxidase (1)
- Neurologie (1)
- Oxidoreduktase (1)
- PRAAS (1)
- PSMC5 (1)
- Pancreatic Beta-Cell (1)
- Phosphorylierung (1)
- Posttranslationale Modifikation (1)
- Prostatakarzinom (1)
- Proteasom (1)
- Proteasom-Assoziierte Störungen (1)
- Proteinbiochemie (1)
- Proteine (1)
- Redoxregulation (1)
- Renin-Angiotensin System (1)
- Renin-Angiotensin-System (1)
- Signalwege (1)
- Syndrom (1)
- TPD52 (1)
- Thiole (1)
- Tumorbiologie (1)
- Zellmigration (1)
- Zytoskelett (1)
- [Fe-S] Cluster (1)
- catalytic activity (1)
- collapsin response mediator protein 2 (1)
- de novo mutations (1)
- extravasation (1)
- geistige Behinderung (1)
- glutaredoxin 2 (1)
- glutaredoxins (1)
- intellectual disability (1)
- katalytische Aktivität (1)
- mutations (1)
- neurodevelopmental disorders (1)
- neutrophil (1)
- oxidoreductase (1)
- posttranslational modification (1)
- prostate cancer (1)
- proteasomes (1)
- proteasomopathy (1)
- protein biochemistry (1)
- reactive oxygen species (ROS) (1)
- redox relay (1)
- signalling pathways (1)
- syndromic (1)
Institute
- Institut für Med. Biochemie u. Molekularbiologie (7) (remove)
Despite the extensive ongoing research, there still exist plenty of diseases whose mechanisms have not yet been fully understood, one such example being proteasome-related disorders. Over the last few years, an increasing number of studies have been initiated
to elucidate their driving pathophysiological mechanisms. Determining the systematic effects of genomic alterations occurring in genes encoding 19S proteasome subunits is a key to comprehend the molecular basis of syndromic intellectual disability (ID) pathogenesis and
the subsequent design of new targeted therapies. Therefore, the main objective of my research was to contribute to the identification of potential drivers of syndromic ID, and thereby pave the way for the development of new targeted therapy approaches. In this regard, my aim was to characterize tissue, proteomic and metabolomic changes in cells from patients with PSMC5 mutations and uncover a potential dysregulation of various biochemical and/or inflammatory pathways.
To this end, I undertook a comparative examination of control and patient T cells expanded from peripheral blood mononuclear cells (PBMCs). First, I assessed the proteasome composition in these samples (both in its denaturized and native form), by means of
SDS-PAGE, native PAGE and western-blotting. Moreover, I determined proteasome chymotrypsin-like activity by measure of Suc-LLVY-AMC peptidase activity assay. In addition, I analysed the activation status of the ER stress and mTOR pathway by RT-PCR and SDS-PAGE /western-blotting prior to a subsequent analysis of T-cell markers.
The data show that the investigated p.(Pro320Arg) and p.(Arg201Trp) de novo heterozygous missense mutations in the PSMC5 gene do not cause haploinsufficiency as the steady-state expression level of the PSMC5/Rpt6 full-length protein does not vary between control and patient cells. Further analysis of control and patient T cells under non-reducing conditions revealed that PSMC5/Rpt6 mutants were less efficiently incorporated into 26S proteasome complexes than their wild-type counterparts. The failure to assemble PSMC5/Rpt6 into fully mature proteasomes was associated with a reduced proteasome chymotrypsin-like activity in patient T cells, as determined by in-plate assays. These data unambiguously demonstrate that both of the p.(Pro320Arg) and p.(Arg201Trp) PSMC5 mutations identified in patients suffering from syndromic ID are loss-of-function mutations. Interestingly, my data further show that proteasome dysfunction in these patients was accompanied by abnormalities in mTOR signalling and T-cell differentiation, as determined by western-blotting and flow cytometry, respectively.
Altogether, our data identified for the first time PSMC5 as a disease-causing gene for
a syndromic form of ID. How proteasome dysfunction caused by PSMC5 variants contributes to disease pathogenesis, remains to be fully determined.
Survival, development, and function of cells depend on numerous signaling pathways or-
chestrating the response to external and internal stimuli. Besides the well-established signaling through reversible phosphorylation, the concept of specific, spatio-temporal redox modifi-
cations of protein cysteinyl and methionyl side chains that regulate the biological function of these proteins is supported by an overwhelming amount of data. Although the specific reduction of protein redox modifications has been studied intensively, the oxidation of protein side chains was thought to be a result of so-called ‘oxidative stress’. However, this term has been increasingly challenged, since signaling pathways depend on specific, spatio-temporal oxidation of target proteins, most likely catalyzed by specific enzymes. The discovery of MICAL (molecule interacting with CasL) proteins evinced
the first examples of specific oxidases in signal transduction in the redox regulation of cellular functions.As part of the semaphorin signaling pathway, MICAL proteins were characterized to stereospecifically oxidize methionyl residues in actin, thereby regulating actin deolymerization, a process important in neurogenesis and cell migration. This oxidation can be reversed by the specific methionine-R-sulfoxide eductase B1. Besides the regulation of actin dynamics, MICALs are involved in the regulation of cell proliferation and
apoptosis, and the production of hydrogen peroxide may qualify them as specific oxidases also for cysteinyl residues.
Class I and class II glutaredoxins (Grxs) are glutathione (GSH)-dependent proteins, that function as oxidoreductases (class I) or mediate cellular iron trafficking (class II). Some members of class I Grxs like human Grx2 are able to complex a [2Fe-2S] cluster and form a dimeric holo complex, which renders them catalytically inactive and is the basis for their function as redox sensors. Class II Grxs like human Grx5 also complex [2Fe-2S] clusters, however these proteins transfer the clusters to other proteins. Both functionally distinct classes share a similar thioredoxin fold and conserved interaction sites for the non-covalently binding of GSH, which is required to complex the [2Fe-2S] cluster. Furthermore, the proteins from both classes contain a highly nucleophilic active site cysteine that would allow both classes to catalyze GSH-dependent oxidoreduction reactions. Despite of these similar features, only class I Grxs are able to form a mixed disulfide with GSH and to reversibly transfer it to protein thiols (de-/glutathionylation). Interestingly, neither class I Grxs nor class II Grxs can effectively compensate the loss of an essential member of the other class. Even though some structural differences were described earlier, the basis for their different functions remained unknown. In particular, the lack of catalytic activity of class II Grxs as oxidoreductases could not be explained. Here, we demonstrate that the different conformations of a conserved lysyl side chain are the molecular determinant of the oxidoreductase or Fe-S transfer activity of class I and II Grxs, respectively. A specific loop structure that is conserved in all class II Grxs determines one lysyl conformation that prevents the formation of a mixed disulfide of the active site cysteinyl thiol with GSH. Using engineered mutants of hGrx2 and hGrx5, we demonstrated that the exchange of the distinct loop between the classes results in a loss of oxidoreductase function of class I hGrx2 and the gain of oxidoreductase activity of class II hGrx5. The altered GSH binding mode also profoundly changes the [2Fe-2S] cluster binding of the engineered mutants and thereby also influences stability of the holo complexes, a pre-determinant for [Fe-S] cluster transfer activity. With the minor shift of 2 Å in a conserved lysyl side chain orientation we were not only able to modify the catalytic activity of two small human mitochondrial proteins, but on a much larger scale also provided evidence for the previously unknown structural basis that determines the function of all class I and class II Grxs.
The oxidoreductase activity of hGrx2 was also analyzed in vivo in a model of doxorubicin cell toxicity. Applying a mass spectrometrical approach, we identified various mitochondrial proteins as targets for redox regulation. Furthermore, our results gave reason to reconsider some common assumptions regarding doxorubicin-induced apoptosis and the protective function of mitochondrial Grx2.
Numerous signalling pathways orchestrate the development, the functions, and the survival of cells, mostly in response to external stimuli. An overwhelming amount of data supports the concept of specific, spatio-temporal redox signalling pathways that affect the redox state of protein cysteinyl side chains and thus the biological function of these proteins. Glutaredoxins (Grxs) and thioredoxins (Trxs) catalyse reversible thiol-disulphide exchange reactions. The cytosolic Grx2 isoform Grx2c is essential for brain development and axonal outgrowth. A reversible dithiol-disulphide switch of CRMP2 has been identified as one of the major targets regulated by Grx2c. This CRMP2 redox switch is toggled in neuronal differentiation. Reduction of CRMP2 thiols induces profound conformational changes, modifying interactions and downstream elements of this redox switch. In [article I] and [manuscript V], we identified the Cys504 of CRMP2 to be the redox regulated residue. We used various in vitro assays with recombinant protein and molecular dynamics simulations to characterise the conformational change. The changes involve the solvent accessible surface area of at least one known phosphorylation site at the C-terminus of the protein. In [article III], we analysed the function of Grx2 and Trx1 in a model for perinatal asphyxia. Trx family proteins exhibit a very complex, cell-type and tissue specific expression pattern following hypoxia/ischemia and reoxygenation, especially Trx1 and Grx2. The results imply the clinical relevance for both proteins in perinatal asphyxia as well as many other neurological disorders. In agreement with the results presented in [articleI], Grx2 may be required for the re-establishment of neuronal integrity and connectivity. Cell shape, all forms of intracellular transport, and cell movement depend on the cytoskeleton, particularly on the fine tuned complex regulation of the dynamic re-arrangement of actin filaments and microtubules. In [article IV], we discuss the redox regulation of this dynamic cytoskeletal remodelling. Taking recent discoveries into account, we focus on redox signalling mechanisms, e.g. reversible thiol and methionyl switches. These switches are specifically controlled by enzymes such as Trx1 and Grx2c, for instance, and not the result of random modification by unspecific oxidants. Methionyl sulphoxidation of actin can be reversed by methionyl sulphoxide reductase (MsrA), promoting actin polymerisation. Human cells express two different Msr enzymes (MsrA and MsrB), that can reduce S- and R-methionyl sulphoxide, respectively. In the gram-positive Streptococcus pneumoniae, on the other hand, both Msr genes and thus enzymes were fused during evolution. In [article II], we characterised the surface-exposed thioredoxin family lipoproteins Etrx1 and 2 and regulators of this Msr (SpMsrAB). A loss of function of both Etrx proteins or SpMsrAB dramatically reduced pneumococcal virulence, enhanced the bacterial uptake by macrophages, and accelerated pneumococcal killing by H2O2 or free methionine sulphoxide. Identification and characterisation of components of this redox regulated system may contribute to the design of new antimicrobials. In [manuscript VI], we investigated the effects of Grx2c expression on cell morphology, migration, and invasion behaviour of cancer cells. Grx2c expressing cancer cells developed dramatic changes in phenotype, including alterations in cytoskeletal dynamics and significantly increased motility and invasiveness. We used quantitative proteomics and phopshoproteomic approaches to characterise the underlying mechanisms. Proteins and pathways regulating cytoskeletal dynamics, cell adhesion, and receptor-mediated signal transduction were detected to be specifically altered. We started a clinical pilot study with patients suffering from clear cell renal cell carcinoma (ccRCC). Grx2c was expressed with significantly higher frequency in ccRCC compared to healthy kidney tissue, associated with a strong trend for locally more advanced tumour stages and a clear tendency for a decreased cancer-specific survival, compared to patients without detectable Grx2c. These results were supported by data from "The Cancer Genome Atlas". In synopsis, the results presented and discussed in these articles and manuscripts, support the concept of specific redox signalling in different models and model organisms. They also demonstrate the importance of the specific redox control of signalling pathways that, in the case of errors or misinterpretations, contribute to pathophysiological alterations. The regulation of the CRMP2 redox switch by Grx2c, for instance, is physiologically essential for brain development, but might lead to cancer progression, if "switched on" in adult tissue. Identification of further interaction partners as well as the development of compounds modulating this redox switch and CRMP2s conformations, will be part of our future research.
The systemic renin-angiotensin system (RAS) is an endocrine system that is mainly known to regulate blood pressure, fluid and electrolyte balance as well as volume homeostasis in the body through different active metabolites, the angiotensin (Ang) peptides. In addition, local renin-angiotensin systems have been discovered in various tissues, including the islet of Langerhans. Starting with angiotensinogen, the precursor of all angiotensin peptides which is cleaved into the decapeptide Ang I by renin, the RAS is divided into three axes. The main classical RAS axis is composed of angiotensin converting enzyme (ACE), angiotensin (Ang) II, and the Ang II type 1 receptor (AT1R), whereas the two alternative RAS axes comprise either ACE2, Ang-(1-7) and the receptor Mas or the aminopeptidase N (APN), Ang IV and the insulin-regulated aminopeptidase (IRAP). The activation of the main ACE/Ang II/AT1R RAS axis has been associated with metabolic syndrome, type 2 diabetes mellitus, and islet dysfunction. The detrimental effects resulting from the pathological activation of this axis have been shown to be attenuated or even abolished by the pharmacological inhibition of components of the main RAS axis. However, the impact of the two alternative ACE2/Ang-(1-7)/Mas and APN/Ang IV/IRAP RAS axes on islet function is less well understood. Previous studies mainly focused on the possible protective actions of Ang-(1-7) via the receptor Mas in insulin-sensitive tissues and on well known risk factors of metabolic syndrome (insulin resistance, hyperglycemia, obesity, hypertension and dyslipidemia). Thus, the impact of this axis on β-cell function and, in particular, insulin production and release was examined in the present study. Glucose and fatty acids have been subjects of diabetic research because they are established pathophysiologically relevant features of the metabolic syndrome and are known to harm β cells, phenomena which are referred to as gluco- or lipotoxicity, respectively. The pathophysiologically relevant factors glucose, saturated fatty acid (FA) palmitic acid (PA), and the methyl ester of the omega-3 fatty acid docosahexaenoic acid (DHA-ME) were used in the present study to characterize the local β-cell RAS as well as β-cell function under pathophysiological conditions. Results of the present work demonstrate the expression of selected components of the RAS in isolated murine islets of Langerhans and the rat insulinoma cell line BRIN-BD11 under basal conditions. The alternative ACE2/Ang-(1-7)/Mas and APN/Ang IV/IRAP RAS axes were activated by high glucose in BRIN-BD11 cells after 24 h. Coincidently with these findings insulin production was found to be increased. In contrast, the expression of components of the main ACE/Ang II/AT1R RAS axis and the Ang II type 2 receptor (AT2R) were not affected under the same conditions (Härdtner et al., 2013). Both FAs, PA and DHA-ME were shown to alter the expression of components of the renin-angiotensin system in BRIN-BD11 cells. PA increased the expression of AT1R, the receptor of the main RAS axis, and of AT2R, whereas that of the receptor of the alternative ACE2/Ang-(1-7)/Mas RAS axis, Mas, appeared to be down-regulated at basal low glucose concentrations (5.5 mM). These effects were accompanied by a dose-dependent reduction of the insulin production and secretion. In contrast, DHA-ME augmented the expression of components of the ACE2/Ang-(1-7)/Mas axis and IRAP at low glucose concentrations, an effect which could be partially enhanced under high glucose conditions (25 mM). At basal glucose concentrations DHA-ME reduced the insulin secretion, whereas it was increased under high glucose conditions. However, the insulin mRNA amount remained unaffected by DHA-ME. Additionally, in contrast to glucose and palmitic acid, DHA-ME significantly increased the production of reactive oxygen species, at least hydrogen peroxide after 30 min. Expression alterations of components of the alternative ACE2/Ang-(1-7)/Mas RAS axis by glucose and PA correlated strongly with the corresponding insulin secretion and production. Therefore, an involvement of the ACE2/Ang-(1-7)/Mas RAS axis in the regulation of insulin secretion and production was hypothesized and validated in primary islets of Langerhans of both Mas-deficient and wild-type mice. Islets were exposed to the preferred natural ligand for Mas, Ang-(1-7), or to its pharmacological agonists or antagonists, respectively....
I have investigated the role played by reactive oxygen species (ROS) generated by the phagocyte NADPH oxidase system in the innate immune response. I first looked at effector functions by asking whether ROS released from phagocytes might be effective in the killing of extracellular bacteria. Since bacteria can be killed in many other ways – for example by proteases or by cationic peptides – I made use of the recently demonstrated capacity of ROS to remove discontinuities from the surface of gold as the basis of an in vivo assay for extracellular ROS. Unlike bacterial killing, this readout system is not affected by enzymes, cationic peptides or other biological anti-bacterial agents. By this means I was able to use wild type mice and a congenic strain which lacks the gene coding for the gp91 subunit of the phagocyte NADPH oxidase to demonstrate that ROS generated by the NADPH oxidase system are indeed found outside the cells during an inflammation in vivo and that their principle source is neutrophil granulocytes rather than tissue macrophages. Since ROS released by these cells will be non-specific in its action it is to be expected that the releasing cell will itself suffer considerable damage. This fits well to the known short life of activated neutrophils and may explain the established fact that their death is dependent on the NADPH oxidase system. The long lived macrophages, in contrast, restrict their production of extracellular ROS. ROS are increasingly being found to be involved in both intra and intercellular signalling processes I looked for an involvement of NADPH oxidase derived ROS in the recruitment of neutrophils to sites of inflammation in vivo. Since the gene coding for the gp91 subunit of the NADPH oxidase is on the X chromosome I made use of a mosaic expression strategy based on X chromosomal inactivation. The results show that indeed ROS serves as a component of the neutrophil recruitment process in the critical early stages of an infection. Possible mechanisms are explored.
Summary Prostate cancer (PCa) is the most common type of cancer found in men from western countries and is the leading cancer death next to lung cancer and colorectal cancer. Proteomic studies on PCa identified a number of differentially expressed proteins and some of them were reported as potential markers, but clinical application of these markers is mostly missing. Most of the expression profiling studies have been carried out on radical prostatectomy specimens, formalin-fixed paraffin-embedded (FFPE) tissue sections, serum, urine and prostate fluids. To define the protein expression pattern of prostate biopsies, in the present study we investigated biopsy samples from benign prostate hyperplasia (BPH) and PCa patients by two-dimensional gel electrophoresis (BPH n=11 and PCa n=12) and mass spectrometry to identify potential biomarkers which might distinguish the two clinical situations. 2-DE results revealed 88 protein spots expressed differentially among hyperplasia and cancer groups with statistical significance. Interesting spots were analyzed by MALDI-TOF-MS-MS and 79 different proteins identified. The important proteins identified included, Prohibitin and NDRG1 tumor suppressor proteins, HSPs, cytoskeletal proteins, enzymes like DDAH1 and ALDH2. Prohibitin expression was investigated in detail at mRNA level and protein level using immunohistochemistry on prostatectomized specimens. We found that the level of mRNA for prohibitin correlates with the increased amount of protein indicating the involvement of changes at transcriptional level. Furthermore, immunohistochemistry revealed no staining in BPH, moderate staining in prostate intraepithelial neoplasia (PIN) and strong staining in PCa. From the list of differentially proteins compared to PCa, TPD52 is over expressed in prostate cancer and also mRNA estimation by real-time PCR confirmed over expression of TPD52 at transcriptional level in cancer. TPD52 is a protein over expressed in prostate and breast cancer due to gene amplification but its exact physiological function is not investigated in detail. In the present study, we explored the responsiveness of LNCaP cells after dysregulation of TPD52 expression. Transfection of LNCaP cells with specific shRNA giving efficient knockdown of TPD52 resulted in a significant cell death of the carcinoma LNCaP cells. As evidenced by the activation of caspases (caspase-3 and -9) and by the loss of mitochondrial membrane potential, cell death occurs due to apoptosis. The disruption of the mitochondrial membrane potential indicates that TPD52 acts upstream of the mitochondrial apoptotic reaction. To study the effect of TPD52 expression on cell proliferation, LNCaP cells were either transfected with EGFP-TPD52 or a specific shRNA. EGFP-TPD52 overexpressing cells showed an increased proliferation rate whereas TPD52-depleted cells showed a reverse effect. Additionally, we demonstrated that the exogenous expression of TPD52 promotes cell migration via ávâ3 integrin in prostate cancer cells through the activation of protein kinase B (PKB/Akt) pathway. In an attempt to identify new interacting proteins for TPD52, GST pulldown assays provided evidence for the physical interaction between TPD52 and Prx1 in LNCaP cells. Further, immunoprecipitation results confirmed this interaction. Our results demonstrates that protein profiling and mRNA studies can be performed on prostate biopsies. Moreover, our study revealed a significant up-regulation of prohibitin in prostate cancer compared to BPH which may be a potential marker to distinguish PCa and BPH. From the results for functional characterization of TPD52, we conclude that TPD52 plays an important role in various molecular events particularly in morphological diversification and dissemination of PCa. It may be a promising target to investigate further in detail to develop new therapeutic strategies to treat PCa patients. Caspases represent a family of cysteine proteases that are regarded as central executioners of apoptotic cell death. Activation of caspase cascade is an essential prerequisite in the induction of apoptosis in cellular systems. So far, in many tumors caspases were shown to be downregulated while anti-apoptotic Bcl-2 is up-regulated. To get insight in their putative role in PCa progression we determined the expression of caspase-1, uncleaved caspases 3 and 6, cleaved (activated) caspases 3 and 6, caspase-9 and antiapoptotic protein Bcl-2 in benign prostate epithelium (BPE) and prostate carcinoma. In the current study 20 prostates were obtained from patients undergoing radical prostatectomy due to PCa. Paraffin embedded prostate whole mounts were cut at (4 µm) and investigated immunohistochemically using anti-mouse monoclonal antibodies directed against caspases 1 and 9, uncleaved caspases 3 and 6, cleaved caspases 3 and 6, and Bcl-2. In BPE all caspases were localized in the cytoplasm of glandular cells. Comparing BPE to PCa, no differences were found for caspase-1, uncleaved caspases 3 and 6 as well as caspase-9. Immunostaining for cleaved caspases 3 and 6, however, revealed a statistically significant reduction in PCa compared to non-neoplastic tissue. Whereas in BPE Bcl-2 protein was detected in the basal compartment of epithelial gland cells no immunostaining was seen in PCa. As our results show a decreased amount of activated caspases may be due to the alterations of posttranslational cleavage rather than expression of caspases 3 and 6. This suggests that the modification in their activation pathway could play an important role during PCa progression.